This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

David Lockhart, Ph.D.
President & Chief Scientific Officer at ReCode Therapeutics


David Lockhart, Ph.D. is ReCode’s president and chief scientific officer with more than 25 years of experience across all phases of drug discovery, drug development, and technology development. Prior to becoming president and CSO of ReCode Therapeutics in January 2022, he served as CEO and president of the company since March 2020. Prior to serving as CEO and President of ReCode, he was CEO and President of its predecessor, TranscripTx from 2014 to 2020. Prior to TranscripTx, he was the Chief Scientific Officer at Amicus Therapeutics from 2006 through 2013. He led a team at Amicus that brought multiple rare disease programs into clinical trials. Previously, he co-founded Ambit Biosciences, serving as Chief Scientific Officer and President for 5 years, during which the company developed a novel kinase profiling technology and new kinase inhibitors for cancer and other diseases. Prior to Ambit, Dr. Lockhart served as Director of Genomics at the Genomics Institute of the Novartis Research Foundation (GNF). Dr. Lockhart began his biotech career at Affymetrix, where he was the primary inventor and developer of gene expression profiling with DNA microarrays.

Agenda Sessions

  • SORT LNP-formulated mRNA for the treatment of Primary Ciliary Dyskinesia